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The study consisted of three objectives: (a) to test the relative prominence and conspicuousness of a warning 
required by US law to be conspicuous; (b) to explore whether or not the conspicuousness of the said warn­
ing can be enhanced graphically; and (c) to develop preliminary data for power analysis that would guide 
decisions related to sample size in future studies. 
Seventeen subjects viewed four over-the-counter drug packages (each with a different style of warning) 
along with ﬁve other products while wearing an eye tracking device. Four styles of warning were used on 
the over-the-counter drug packages: no outline and no ﬁll, outline and no ﬁll, no outline and ﬁll, and outline 
and ﬁll. The surface area and the placement of the warnings were held constant across all four designs and 
were consistent with those on commercially available products. Collected data were broken into ﬁve zones: 
warning, brand name, strength, product beneﬁt and net weight. 
Despite the fact that US law requires it to be conspicuous, the tested warning was signiﬁcantly less no­
ticeable than the brand name (objective one) for all dependent variables analyzed (a = 0.05). No signiﬁcant 
difference was indicated for the varied warning designs (objective two). This could be because not much 
can be done to enhance prominence when constrained to the limited space that is typically used for 
such warnings or because of the limited sample size. Power calculations suggest that a sample size of nearly 
200 subjects would be required to detect a 2.5 s mean difference at 80% conﬁdence (objective three). 
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INTRODUCTION 
Risk is pervasive. Whether we are at home, at work or travelling from one place to another, risks are 
involved. Warnings are intended to help reduce or eliminate risks. However, for a warning to be effec­
tive, there must be exposure to the warning, attention to the warning, active processing of the warning, 
comprehension and agreement with the warning, storage in memory (as well as search and retrieval), 
response selection and response performance. Failures at any of these stages have the potential to reduce 
a warning’s effectiveness.1–4 
Recent years have seen an increase in warning-related research. Researchers attribute this to varied 
reasons; the three main reasons are as follows:5 
•	 Increasing healthcare costs (in the USA and around the world). 
•	 Increasing importance of warnings in litigation and court cases. 
•	 Increasing emphasis on warnings by organizations such as the US Environmental Protection 
Agency) and the US Occupational Safety and Health Administration. 
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Warnings are frequently classiﬁed into three large spheres. Those that 
•	 Prevent dangerous practices, such as smoking in gas stations or being exposed to sunlight while 
taking certain drugs. 
•	 Catalyse behavioural change; a warning suggesting protective gear is one such example. 
•	 Enable informed decisions. For example, a warning that indicates the risks associated with alcohol 
consumption during pregnancy or statutory cigarette warnings.6 
The model. We frame our study within the context of an information processing model. Information 
processing models focus on the stages that warnings pass through while being transmitted from the 
environment to the user. Such models take into account multiple facets that have the potential to 
inﬂuence the success or failure of the message.6 Information processing theories often mention that 
the information passes through stages in serial fashion and that failure at any stage will lead to failure 
of subsequent steps. 
A commonly used theory of information processing indicates that the following four steps must be 
completed for the warning to be effective.2–4,7,6 
1. The information must be noticed. 
2. It must be encoded into memory. For this to happen, the message must be gathered through 
perceptual systems and converted from an external representation into an internal one. 
3. The encoded message must then be comprehended. 
4. It must, ﬁnally, move the reader to the appropriate action. 
Because of the sequential and serialized nature implicit in information processing, many pieces of leg­
islation and regulation mandate that certain informational items appear ‘conspicuously’ or ‘prominently’ 
on package labels (see Table 1). Without sufﬁcient prominence, an item is not noticeable, precluding the 
ability of the consumer to proceed with further processing. Although a limited number of ofﬁcial docu­
ments do prescriptively address things like minimum type size and make vague statements like ‘sufﬁcient 
contrast’, the  deﬁnitions of ‘prominence’ and ‘conspicuousness’ are vague throughout the mandates. 
For this study, we investigated the relative prominence of the warning, ‘This package for households 
without young children’ (stage one of the information processing model). The Poison Prevention 
Packaging Act of 1970, 15 U.S.C. pages 1471–1476, requires child resistant closures on most hazardous 
household substances; this includes drugs as deﬁned in Section 201 of the Federal Food, Drug and 
Cosmetic Act, 21 U.S.C. page 321.8 One size of over-the-counter (OTC) product may be exempted 
from the requirement for a child resistant feature, provided it is ‘conspicuously labelled’ with 
the aforementioned warning. Yet previous research suggests that across several OTC products 
containing acetaminophen, this warning was consistent in both 
•	 Its design (most were present in the lower left hand corner of the package and of consistent size). 
•	 Its inability to garner attention as measured by eye tracking.9 
This led us to wonder ‘if constrained by available space on the principal display panel (PDP), is 
there a way that warnings could be graphically enhanced to garner attention?’ In other words, if man­
ufacturers are limited to a small space in the lower left hand corner of these packages, is there anything 
that be carried out to make the warning more noticeable? Holding the warning placement to the lower 
left hand corner of the PDP and limiting the allowable surface area to a 43 mm x by 4 mm rectangular 
space (172 mm2), an area and placement based on the commercial products we used for previous 
study,9 we investigated the effects of two design elements, outline and ﬁll, on the noticeability of 
the warning as measured by eye tracking. 
This is in accordance with the ‘theory of pre-attentive processing’, described by Wogalter et al. 
as follows: 
‘Pre-attentive processing’ suggests that information (e.g. a warning), if designed properly with re­
spect to the background, can ‘pop out’ and attract attention without conscious control on the part 
of the individual. For example, if an individual is shown a random conﬁguration of 100 equal size 
dots, a single red dot embedded in 99 blue dots will ‘leap off the page’ and be detected prior to any 
conscious, attentive processing on the part of the individual.10 
  
Table 1. US documents that mandate and deﬁne prominence and conspicuousness. 
Document Area Description 
21 CFR Section 207.35(b)(3) Prescription Requests the presence of an NDC on all drug labels 
drugs and other drug labelling including the label of any 
prescription drug container furnished to a consumer. 
If the NDC is shown on a label, it shall appear 
‘prominently’ in limited locations. 
21 CFR Section 201.15 (a)(1–6) Drugs General labelling provisions – Reasons for failure 
with regard to prominence and conspicuousness. 
Failure to appear. Failure to present in enough 
places. Failure to extend over the available area. 
Insufﬁciency of space for prominent placement 
(for varied reasons, including devoting greater 
conspicuousness to other label elements). Size or 
style of type, insufﬁcient contrast, obscuring 
designs, crowding. 
Medical Device User Fee and Device Requires a device or attachment to the device to 
Modernization Act (MDUFMA) bear prominently and conspicuously the name of the 
of 2002 (Public Law 107-250) – manufacturer, a generally recognized abbreviation of 
Amends Section 502 of the Federal such name or a unique and generally recognized 
Food Drug and Cosmetic Act symbol identifying the manufacturer. 
Guidance for Industry and FDA Device Prominent and conspicuous is deﬁned in a guidance 
staff: compliance with Section 301 compendium to MDUFMA as ‘A manner of marking 
of the MDUFMA of 2002, as a device, as required by section 502(u) of the Act, such 
amended – Prominent and that the manufacturer’s mark is apparent to the user 
Conspicuous Mark of Manufacturers under ordinary conditions of use.’ 
on Single-Use Devices. 
27 CFR Chapter 8 Subchapter II Alcoholic Surgeon General’s required warning ‘GOVERNMENT 
Section 215b beverages WARNING: (1) According to the Surgeon General, 
women should not drink alcoholic beverages during 
pregnancy because of the risk of birth defects (2) 
consumption of alcoholic beverages impairs your 
ability to drive a car or operate machinery, and may 
cause health problems’ is required to be ‘conspicuous 
and prominently’ placed on the container in 
‘contrasting background’ 
27 CFR Section 16.22 Alcoholic Required warning shall be stated on brand label or 
beverages separate front label, back or side panel. Separate from 
other information. Readily legible under ordinary use 
conditions. Statement beyond ‘GOVERNMENT 
WARNING’ may not appear in bold. Remaining text 
shall not be compressed in such a manner that the 
warning is not readily legible. Containers of 8 ﬂ oz or 
less = text not less than 1 mm. 8 ﬂ oz–3 l = not  smaller  
than 2 mm. Greater than 3 l = not smaller than 3 mm. 
40 CFR Section 156.10 Pesticides All words, statements, graphic representations, designs 
or other information required on the labelling by the 
Act or the regulations in this part must be clearly 
legible to a person with normal vision and must be 
placed with such conspicuousness (as compared with 
other words, statements, designs or graphic matter on 
the labelling) and expressed in such terms as to render 
it likely to be read and understood by the ordinary 
individual under customary conditions of purchase and 
use. Six points or larger type. Clear and contrasting 
background. Not obscured or crowded. 




1. To investigate the conspicuousness of the warning (stage 1 of the information processing model) 
relative to other label elements, speciﬁcally the brand name, strength, net contents and product 
beneﬁt. 
2. To explore how varying graphic elements (an outline and background ﬁll) impact its noticeability 
when the placement and surface area of the warning are held constant. 
3. To develop preliminary data for power analysis that would guide decisions related to sample size 
in future studies. 
MATERIALS AND METHODS 
Test participants. Useable data were collected from 17 participants from a population that consisted 
primarily of students between the ages 18 and 25 years following procedures approved under IRB 
06–054. Participants were at least 18 years or older and were not legally blind. Upon arrival, partici­
pants were assigned a ‘participant number’ and were characterized by gender and visual acuity. 
Visual acuity test. Each participant’s visual acuity was tested and recorded using a near point visual 
acuity card manufactured by Dow Corning Ophthalmic. The subjects were asked to hold the card 
approximately 16 in. from their eyes and were asked to read the lowest line possible. This line corre­
sponded with the subject’s near point visual acuity (e.g. 20/20 and 20/30). 
Instrument – Applied Science Laboratories eye tracker. An Applied Science Laboratories 501 
head mounted bright pupil system (Boston, MA, USA) was used to record participant’s eye move­
ments. Once the eye tracking equipment was comfortably placed on the head, the calibration sequence 
began. For calibration and testing, subjects were seated at a special table ﬁxtured with a glass pane and 
a chin rest. This set-up allowed subjects to examine packages at a consistent and ﬁxed distance from 
their eyes. The calibration sequence employed a ﬂoating technique that consisted of nine dots distrib­
uted equally across the pane of glass. By ﬁxing the distance and limiting subject movement, the set-up 
minimized parallax error, enhancing accuracy of the tracking of the gaze trail on the package surface. 
Following calibration, participants were instructed that they were being asked to examine a series of 
items that appeared on a shopping list that they had been given (see Table 2). They were asked to re­
view packages as they would in the store when making a purchase decision for their household (sum­
mary of the experimental design shown in Figure 1). They were told that they could view any side 
of the package that they wished but were instructed to press packages against the glass pane (the cali­
brated plane) as they did. 
Following this instruction, nine packages were handed to the subject for viewing in an order that 
was counterbalanced across subjects. Participants viewed each of the nine packages for a time period 
of 10 s before being handed the next product. Ten seconds was chosen as a conservative estimate 
because sources indicate that consumers generally take 5–7 s examining packages while shopping.11 
Table 2. The nine packages used for the experiment. 
Number Package Warning characteristics 
Brand Product Size Text colour Background Outline 
1 Vanish Toilet bowl cleaner 1.7 oz N/A N/A N/A 
2 Tyvedron Pain reliever 24 gel caps White Dark blue No 
3 Nature Valley Almond granola bars 7.4 oz N/A N/A N/A 
4 Tyvedron Pain reliever 24 gel caps White Dark blue White 
5 Grand River Falls Tomato basil crackers 1.75 oz N/A N/A N/A 
6 Tyvedro Pain reliever 24 gel caps Dark blue White No 
7 Elsa’s Story Black pepper crackers 5.29 oz N/A N/A N/A 
8 Tyvedron Pain reliever 24 gel caps Dark blue White Dark blue 




Figure 1. Experimental design. 
This is also consistent with the studies performed by Krugman et al. where subjects were eye tracked 
while viewing tobacco advertisements. The time spent by the average reader ranged between 3.2 and 
14.7 s when they viewed the advertisements without any time restrictions.12 
Stimulus material. As mentioned, the size, placement and content of the warning on the PDPs were 
held constant (see Figure 2); the warning design was not. The warning text was comprised of eight-
point Swiss 911 Ucm BT font in navy blue (Pantone Matching System 184–1). Warnings were created 
to test for an effect of two design elements, outline and ﬁll, on the ability to garner subject attention. 
Two levels of each of the elements were crossed such that four designs were tested (See Figure 2 and 
3): 
• Warning 1 (no outline and no ﬁll). 
• Warning 2 (outline and no ﬁll). 
• Warning 3 (no outline and ﬁll). 
• Warning 4 (outline and ﬁll). 
Statistical analysis. Eye tracking data were collected in the form of video ﬁles and analyzed using 
Gaze TrackerW (purchased through Applied Science Laboratories, Boston, MA) eye tracking 
analysis software. All dependent variables tested were ﬁrst examined for an effect of run order; 
no effect of order was suggested at αa = 0.05 for all variables. During the analysis phase of the 




Figure 2. Principal display panels of the four Tyvedron packages used as stimulus. 
The ﬁve zones were brand name, warning (four levels), net content, strength and product beneﬁt 
(i.e. nondrowsy). Brand name, net content, strength and product beneﬁt were identical on all four 
packages of Tyvedron used in the study. Only the warning zone was changed (see Figures 2 
and 3). Three dependent variables were used in the analyses: 
1. Time spent in zone (a variable response). 
2. Probability of a zone being hit ﬁrst (zone hit ﬁrst; yes/no; a binary response). 
3. The number of visual hits to a zone (a discrete response variable). 
Statistical analysis was then carried out using SAS version 9.2 (SAS Institute Inc., Cary, NC, 
USA).13 Zone, package, gender and their interactions were included in the model as ﬁxed independent 
variables, and subject was considered a random factor in the analysis of variance. Time in zone, prob­
ability of a zone being hit ﬁrst and visual ‘hits’ to a zone were considered response variables. Normal­
ity and equality of variances assumptions were checked visually using normal plots and side-by-side 
box plots. Because of right skewness, both time and hits had to be transformed (log-transformed for 
time and square root for hits). Least square mean estimates and 95% conﬁdence intervals were carried 
out for the sake of post-hoc comparisons. 
RESULTS AND DISCUSSION 
Dependent variable – total time spent in a zone 
When time was the dependent variable, zone (p < 0.0001), zone x gender (p = 0.0527) and package x 
gender (p = 0.0300) were found to be signiﬁcant (a = 0.05). Consistent with previous work,9 brand 




Figure 3. Design of warnings (dimensions are in millimetre; those marked with an asterisk correspond 
to the centre of the outline). 
Figure 4. Zones of test stimulus. 
the dependent variable of interest (see Figure 5). The zone warning received signiﬁcantly less attention 
than all other zones tested except for strength, only garnering an estimated 0.03 s per viewing. 
The analysis of variance also indicated a marginal effect of the interaction term zone by gender 
on time per zone (p = 0.0527). To further explore this effect, pairwise comparisons were made 
using least square mean differences. When all ﬁve zones were examined for gender effects, only 
zone 1, warning, was suggested to be signiﬁcant (p = 0.0344). Male subjects spent more time 
(0.08 s) on the warning zone when compared with their female (0.01 s) counterparts. This contra­
dicts prior research speciﬁcally designed to research the effect of gender on the noticeability of 
warning labels. The reviewed literature suggests female subjects have a greater tendency to look 




Figure 5. Estimate of time spent in a zone. 
Total time in zone 1 – warning. To speciﬁcally explore how varying the graphic and textual elements 
(an outline and background ﬁll) impacted the time spent on the warning label when its placement and 
surface area were held constant, we conducted a second analysis that just looked at the time spent on 
zone 1 (the warnings) (see Table 3) in the form of a 2 x 2 factorial that considered ﬁll and outline each 
at two levels as well as the interaction term. Because of the failure of the data to meet model assump­
tions, data were log-transformed for the statistical analysis. This analysis did not provide evidence of 
an effect of warning design on the time spent in the warning zone (p > 0.05). 
Table 3. Time spent on Zone 1 – warning (averaged across all the subjects). 
Warning Treatment Total time spent (seconds) 
Warning 1 (no outline, no ﬁll) 4.0 
Warning 2 (outline, no ﬁll) 3.9 
Warning 3 (no outline, ﬁll) 6.3 
Warning 4 (outline, ﬁll) 6.7 
Probability of a zone being hit ﬁrst 
We also analyzed the ability of each zone to draw the eye, i.e. the probability of a zone being hit ﬁrst 
(see Table 4). Statistical analysis indicated that the probability of being visually ‘hit ﬁrst’ was signiﬁ­
cantly affected by the zone (p < 0.0001); i.e. some zones were more likely to be hit ﬁrst than others. No 
other factors provided evidence of a signiﬁcant difference (a = 0.05). Post-hoc pairwise comparisons 
suggest that brand name (zone 2) had a signiﬁcantly higher probability of being hit ﬁrst (52%) than 








(no outline, no ﬁll) 
Package with 
warning 2 
(outline, no ﬁll) 
Package with 
warning 3 




Warning (Zone 1) 
Brand name (Zone 2) 
Strength (Zone 3) 
Product beneﬁt (Zone 4) 





















Please note that eye tracking data were not available for one subject viewing the package with warning 2. 
Figure 6. Probability of a zone to be hit ﬁrst. 
Visual hits in a zone 
Further analysis examined data for an effect on the number of visual hits garnered. As before, the fac­
tors for consideration were subject, zone, package and gender, as well as all interactions. Only subject 
was considered a random effect. Zone had a signiﬁcant effect on the number of hits (p < 0.0001), and 
the interaction term package x gender was also indicated to be signiﬁcant (p = 0.0043). Post-hoc, least 
square mean comparisons suggested that the brand name (zone 2) received a statistically signiﬁcant 
greater amount of attention when the number of hits to the zone was the dependent variable (See 
Figure 7. Estimate of number of hits in a zone. 
Table 5. Frequency table: number of hits and average number of hits on Zone 1 – warning 
(across all subjects). 
Treatment 
Total number of hits by Warning 
type (for all subjects) 
Average number of 
hits per subject 
Warning 1 (no outline, no ﬁll) 
Warning 2 (outline, no ﬁll) 
Warning 3 (no outline, ﬁll) 












Figure 7). Strength and product beneﬁt were preferentially attended as compared with warnings and 
net contents at a = 0.05. 
Number of hits with respect to the treatments in zone 1 – warning. Data were also analyzed to 
explore objective 2, whether or not graphic elements could be manipulated to create a warning that 
garnered more attention, despite being constrained by placement and area. Preliminary analysis of zone 
1 data indicated that when the dependent variable was the probability of ﬁrst hit, only ﬁve subjects 
(two men and three women) in total hit the warning zone (zone 1) ﬁrst (see Table 4). Of these, warn­
ings 3 and 4 (no outline and ﬁll and outline and ﬁll, respectively) recorded two hits each, whereas 
warning 2 (outline and no ﬁll) was hit ﬁrst once. The frequency with which people hit each of the four 
warning zones was also examined. This data are presented in Table 5. 
Data were too limited to provide meaningful statistical analysis. Although the limited data preclude 
the ability to provide conclusive results regarding the effect of outline and ﬁll to garner attention, we 
can observe the following: there were no ﬁrst hits to warning 1, no outline/no ﬁll (see Figures 2 and, 3 
and Table 4). Warnings similar in design to this (no outline and no ﬁll) are currently being used on 
many of the OTC drugs in the market that are not child resistant. 
CONCLUSIONS 
Our study comprised of three objectives: 
1. To test the relative prominence of a warning required by US law to be conspicuous when com­
pared with other elements of the same label. 
2. To explore how varying the graphic elements (an outline and background	 ﬁll) impacted its 
noticeability when the placement and surface area of the warning were held constant. 
3. To develop preliminary data to be used in a power analysis for future studies. 
Objective 1. Consistent with other work, the warning was less noticeable than brand name for all 
variables measured (time in zone, probability of ﬁrst hit and number of hits to zone) at a = 0.05. Com­
parisons of the warning with the other zones (strength, net contents and product beneﬁts) were more 
varied (see Figures 5–7). 
Objective 2. With regard to inferences relating to objective 2, the ability of varied graphic elements to 
garner consumer attention, our sample size (n = 17) severely limited our ability to make statistical 
inferences. This was despite the fact that it was typical for an eye tracking study.17 Regardless, the fact 
that the warnings designs were trending in the expected direction (see Tables 4 and 5) encourages 
future study. Before future study can begin, a power analysis is needed. 
Objective 3. Power analyses (see Figure 8) were performed. Between subject, variance (s 2 = 38.69) 
was considered equal; two expected mean differences (1.5 and 2.5 s) for the time spent in zone 1 
(warning) were used in the power analysis. The analysis indicates that a sample size of over 980 




subjects would be required for expected mean difference of 1.5 s and that 190 subjects would be 
required for 2.5 s to achieve 80% power. 
That said, this study provides several interesting implications for future research. Eye tracking as a 
method for the objective evaluation of attention has not been used very often in the ﬁeld of pack­
aging,14,18–20 and of these studies, several track eye movement as subjects view a labels on a computer 
screen, as opposed to allowing them to freely manipulate the package.18,19 Tracking on a computer 
screen requires a ﬂattened image of the graphic information be presented, forcing exposure to all six 
faces of the package. Our techniques allow subjects to freely manipulate the package by rotating it 
to any face that they desire. As such, the study presented herein is among the ﬁrst to track subjects 
on real packages, providing a more ecologically valid context for the collection of data regarding at­
tentive behaviour. 
This represents a methodology that has the potential to accurately characterize the attentive 
behaviours of individuals, thereby objectively evaluating the effectiveness of varied elements of 
package design. 
LIMITATIONS 
We purposefully limited our study’s scope such that it examined the ability of a warning, required by 
law to be conspicuously displayed, to garner attention as measured with our Applied Science Labora­
tories 501 eye tracking device. Although attention is requisite to comprehension and action, it is but a 
single step in information processing. As such, we are limited in our ability to conjecture about the suc­
cess or failure of the message in conveying information. Additionally, it should be noted that other fac­
tors, not collected or reported herein, have the potential to signiﬁcantly inﬂuence the attentive 
behaviours of subjects. For instance, Sansgiry and Cady21 found that elderly consumers ‘were more 
involved in the decision making process to purchase OTC medications . . .. The elderly not only pur­
chase and spend more money on medications but also read OTC labels completely.’ Key factors, such 
as drug familiarity and consumer involvement with the drug, were not recorded and could have a 
signiﬁcant effect in ﬁndings. Additionally, our subject population, composed of college students, is 
not generalizable. 
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